Anda Pharmaceuticals, Inc. Sustainability Profile
Anda Pharmaceuticals, Inc., a prominent player in the pharmaceutical distribution industry, is headquartered in the United States. Founded in 2000, the company has established itself as a key provider of generic and specialty pharmaceuticals, catering to a diverse range of healthcare needs across the nation. With a strong operational presence in major regions, Anda Pharmaceuticals focuses on delivering high-quality products that include prescription medications, over-the-counter drugs, and healthcare supplies. Their commitment to affordability and accessibility sets them apart in a competitive market. Recognised for their efficient distribution network and customer-centric approach, Anda Pharmaceuticals has achieved significant milestones, including strategic partnerships that enhance their product offerings. As a trusted name in the industry, they continue to play a vital role in improving patient outcomes through innovative solutions.
DitchCarbon Score
How does Anda Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Anda Pharmaceuticals, Inc.'s score of 41 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Anda Pharmaceuticals, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years, as indicated by the absence of reported figures. The company is a current subsidiary of AbbVie Inc., which influences its climate commitments and emissions reporting. While Anda Pharmaceuticals has not set its own reduction targets, it inherits sustainability initiatives from its parent company, AbbVie Inc. This includes participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are aimed at reducing greenhouse gas emissions in line with climate science. The cascading of these initiatives suggests a commitment to addressing climate change, although specific targets or achievements for Anda Pharmaceuticals are not detailed. As part of its corporate family, Anda Pharmaceuticals aligns with broader industry standards and practices, reflecting a growing emphasis on sustainability within the pharmaceutical sector. However, without specific emissions data or reduction targets, the company's individual climate impact remains unclear.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2005 | 2010 | 2011 | 2012 | 2015 | 2016 | 2017 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 28,218,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 59,189,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Anda Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Anda Pharmaceuticals, Inc.'s Location?
Anda Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Anda Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
